Polyzos, Aristides <br/><br/>
Docetaxel in combination with irinotecan (CPT-11) in platinum-resistant paclitaxel-pretreated ovarian cancer.  [electronic resource] 

 -  Anticancer research   
 - 3559-64 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study 
<br/><br/><label>ISSN: </label>0250-7005 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Antineoplastic Combined Chemotherapy Protocols--adverse effects<br/>Camptothecin--administration & dosage<br/>Cisplatin--pharmacology<br/>Docetaxel<br/>Drug Resistance, Neoplasm<br/>Female<br/>Granulocyte Colony-Stimulating Factor--administration & dosage<br/>Humans<br/>Irinotecan<br/>Middle Aged<br/>Ovarian Neoplasms--drug therapy<br/>Paclitaxel--pharmacology<br/>Prospective Studies<br/>Recombinant Proteins<br/>Taxoids--administration & dosage